Fat fighting liraglutide based nano-formulation to reverse obesity: Design, development and animal trials

• Published in: International journal of pharmaceutics 2023-03, Vol.634, p.122585-122585, Article 122585
• Main Authors: Jakhar, Dheeraj Kumar, Vishwakarma, Vishal Kumar, Singh, Raghuraj, Jadhav, Krishna, Shah, Sadia, Arora, Taruna, Verma, Rahul Kumar, Yadav, Harlokesh Narayan
• Format: Article
• Language: English
• Subjects: Animals; Caco-2 Cells; Chitosan; Eudragit@S100; Glucagon like peptide-1; Humans; Hypoglycemic Agents; Liraglutide; Liraglutide - pharmacology; Liraglutide - therapeutic use; Mice; Nanoparticle; Obesity; Polymethacrylic Acids
• ISSN: 0378-5173; 1873-3476
• DOI: 10.1016/j.ijpharm.2023.122585

[Display omitted] Obesity is a metabolic disease, which is one of the major causes of morbidity and mortality, where therapeutic options are limited. Treatment of obesity is necessary as it is associated with fatal complications like diabetes mellitus, cardiovascular disease, non-alcoholic fatty liver disease, osteoarthritis, and many more. Liraglutide (Lir), a synthetic analogue of Glucagon-like Peptide-1 (GLP-1), is the FDA approved anti-obesity drug, however, its major limitation is its clinical application which needs frequent parenteral injections. To address the issue of regular injection, we have synthesized a fat fighting oral nano-formulation of liraglutide with a sustained release feature, which was evaluated against high fat diet (HFD) induced obesity in mice. Experimental obesity was induced in mice by feeding HFD for 26 weeks. Lir nanoparticles (NP) were fabricated with chitosan via ion-gelation technique and were coated with Eudragit@S100 to protect the drug in harsh gastric conditions. Physiochemical characterization of Eu-Lir-Cs-NP demonstrated a small particle size of 253.1 ± 1.21 nm with ∼ 9.74 % loading and ∼ 72.11 % encapsulation efficiency of the drug. In-vitro studies showed successful cellular uptake of NP in Caco-2 cells and were stable in various enteric fluid pH conditions. Eudragit@S100 coated chitosan NP were able to protect the drug from harsh gastric pH conditions with more than ∼ 74% of recovery. Treatment of two weeks of liraglutide Eu-Lir-Cs-NP (0.1, 0.2 and 0.4 mg/kg, orally; twice daily) moderately reduces obesity in mice as evidenced by a reduction in the body weight, blood glucose, serum total cholesterol, serum triglyceride, serum resistin and serum insulin level of mice. In addition, significant reduction of liver weight, abdominal white adipose tissue, and hepatic oxidative stress were noted. Our results suggest that chitosan-based NP of liraglutide can be an effective and convenient formulation for the management of obesity.